(:ADRO)

Oct 05, 2020 09:00 am ET
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the closing of its merger with Aduro Biotech,...
Oct 01, 2020 04:05 pm ET
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Aug 03, 2020 04:05 pm ET
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand (APRIL) and Stimulator of Interferon Genes (STING) pathways for the treatment of cancer,...
Jun 24, 2020 08:15 am ET
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Jun 02, 2020 07:35 am ET
Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Jun 02, 2020 07:30 am ET
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
Aduro Biotech, Inc. (“Aduro”) (NASDAQ: ADRO) and Chinook Therapeutics, Inc. (“Chinook”), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases,...
May 19, 2020 08:15 am ET
Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
May 04, 2020 04:15 pm ET
Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Mar 09, 2020 04:15 pm ET
Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Feb 24, 2020 04:15 pm ET
Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts on...
Feb 19, 2020 08:15 am ET
Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York, New York on...
Feb 06, 2020 04:15 pm ET
Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Jan 09, 2020 04:15 pm ET
Aduro Biotech Announces Corporate Restructuring
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the immune system cGAS-STING and APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today...
Nov 08, 2019 04:05 pm ET
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at th
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Nov 07, 2019 04:05 pm ET
Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Oct 02, 2019 04:05 pm ET
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Sep 30, 2019 04:05 pm ET
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global Healthcare Conference in New York, New York on Friday, October 4, 2019 at 8:55 am ET....
Sep 04, 2019 08:30 am ET
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamo
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Sep 03, 2019 04:05 pm ET
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright 21st Annual Global Investment Conference in New York, New York on...
Aug 01, 2019 04:05 pm ET
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Jun 02, 2019 11:45 am ET
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Adva
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
May 15, 2019 05:06 pm ET
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
May 15, 2019 05:05 pm ET
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
May 07, 2019 04:05 pm ET
Aduro Biotech Reports First Quarter 2019 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,...
Apr 22, 2019 08:15 am ET
Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced the appointment of Dimitry S.A....
Apr 18, 2019 04:05 pm ET
Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced the appointment of Frank Karbe...
Apr 17, 2019 04:05 pm ET
Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced that abstracts pertaining to the...
Apr 10, 2019 08:40 am ET
Analysis: Positioning to Benefit within Pepsico, Arista Networks, Titan International, Northern Dynasty Minerals, Aduro Biotech, and Corning — Research Highlights Growth, Revenue, and Consolidated Res
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Pepsico, Inc. (NASDAQ:PEP), Arista Networks, Inc. (NYSE:ANET), Titan...
Apr 01, 2019 08:00 am ET
Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright Global Life Sciences Conference in London, United Kingdom on Monday,...
Mar 07, 2019 08:00 am ET
Aduro Biotech to Present at Two Upcoming Investor Conferences in March
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences: 39th Annual Cowen Health Care Conference in Boston, Massachusetts on Wednesday, March 13th at 8:00 am ET. 29th...
Feb 28, 2019 08:00 am ET
Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019 in Atlanta, GA....
Feb 27, 2019 04:05 pm ET
Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an important year for Aduro as we prioritized our core technologies and determined a go-forward strategy...
Feb 21, 2019 08:15 am ET
Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, New York on...
Feb 21, 2019 08:00 am ET
Aduro Announces Changes to its Board of Directors
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the appointment of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals, to its Board of Directors effective February 19, 2019. In addition, Frank McCormick, Ph.D., F.R.S., a director...
Feb 14, 2019 07:35 am ET
Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indicati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Trade Desk Inc. (NASDAQ:TTD), Aduro Biotech, Inc. (NASDAQ:ADRO),...
Feb 11, 2019 08:00 am ET
Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes (STING) pathway activator, in combination with YERVOY® (ipilimumab), an...
Jan 30, 2019 08:00 am ET
Aduro Biotech Announces Strategic Reset
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a strategic reset to focus on Aduro’s core strengths – discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand...
Jan 03, 2019 08:00 am ET
Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California on...
Dec 18, 2018 04:15 pm ET
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway Inhibitor program for the research and development of novel...
Dec 18, 2018 03:15 pm ET
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases.
Dec 12, 2018 08:00 am ET
Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as part of their ongoing research to study intratumoral stimulator of interferon...
Dec 03, 2018 08:00 am ET
Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use as a treatment for multiple myeloma (MM) at the 60th American Society of...
Nov 09, 2018 07:30 am ET
Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator, at SITC's 33rd Annual Meeting in...
Nov 06, 2018 04:16 pm ET
Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C. The event will feature special guest speaker Jason J. Luke, M.D.,...
Nov 02, 2018 07:45 am ET
New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shutterfly, Inc. (NASDAQ:SFLY), Aegion Corporation (NASDAQ:AEGN), Columbia...
Oct 30, 2018 04:01 pm ET
Aduro Biotech Reports Third Quarter 2018 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third quarter of 2018 was $23.1 million, or $0.29 per share, and for the nine months ended September 30, 2018 net...
Oct 26, 2018 04:01 pm ET
Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2018 in...
Oct 01, 2018 04:05 pm ET
Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that four separate abstracts from its research and development portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from...
Sep 25, 2018 04:45 pm ET
Aduro Biotech to Present at Two Investor Conferences in October
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following upcoming investor conferences: Cantor Fitzgerald 2018 Global Healthcare Conference...
Sep 19, 2018 09:00 am ET
Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical officer effective October 1, 2018. Dr. Sacks will continue to provide counsel to the company and facilitate...
Sep 04, 2018 04:06 pm ET
Aduro Biotech and Dana-Farber Cancer Institute Publish Data Highlighting Immunosuppressive Impact of APRIL in Multiple Myeloma in Leukemia
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer reviewed paper in Leukemia authored by scientists from the Dana Farber Cancer Institute and Aduro as part of their ongoing collaboration to study the role of APRIL (A...
Sep 04, 2018 04:01 pm ET
Aduro Biotech Presents Preclinical Data for BION-1301, a First-in-Class Antibody Targeting Human APRIL, at the 2018 European Congress of Immunology
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that preclinical data for its first-in-class anti-APRIL antibody BION-1301 was presented at the 5th European Congress of Immunology in Amsterdam, The Netherlands. Data from the preclinical studies...
Aug 29, 2018 04:01 pm ET
Aduro Biotech to Present at the 20th Annual H.C. Wainwright Global Investment Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 20th Annual H.C. Wainwright Global Investment Conference in New York, NY on Wednesday,...
Aug 29, 2018 07:50 am ET
Recent Analysis Shows Clearwater Paper, Aduro Biotech, Comtech Telecommunications, Ferroglobe, Badger Meter, and Donnelley Financial Solutions Market Influences — Renewed Outlook, Key Drivers of Growt
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater Paper Corporation (NYSE:CLW), Aduro Biotech, Inc....
Aug 22, 2018 04:01 pm ET
Aduro Biotech Granted Composition of Matter Patent for Novel Human APRIL Binding Antibodies
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the United States Patent and Trademark Office has issued a new composition of matter patent related to altered APRIL-binding antibodies, further enhancing the company’s B-select intellectual...
Aug 01, 2018 04:01 pm ET
Aduro Biotech Reports Second Quarter 2018 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the second quarter ended June 30, 2018. Net loss for the second quarter of 2018 was $24.4 million, or $0.31 per share, and for the six months ended June 30, 2018 net loss was...
Jun 29, 2018 07:45 am ET
Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder BioPharmaceuticals, TrueCar, and Aduro Biotech — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Newfield Exploration Company (NYSE:NFX), Heritage Insurance Holdings, Inc....
Jun 07, 2018 04:01 pm ET
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for the treatment of advanced lung cancer. ADU-214 is an immunotherapy based on Aduro’s live,...
May 17, 2018 08:00 am ET
Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill Downs, Incorporated (NASDAQ:CHDN), Nordic American Tankers...
May 10, 2018 04:01 pm ET
Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Thursday, May 17,...
May 02, 2018 04:01 pm ET
Aduro Biotech Reports First Quarter 2018 Financial Results
Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter ended March 31, 2018. Net loss for the first quarter of 2018 was $21.5 million, or $0.28 per share, compared to net loss of $21.8 million, or $0.32 per share,...
Apr 17, 2018 04:01 pm ET
Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting
BERKELEY, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that data from three of the company’s programs were presented at the American Association for Cancer Research (AACR) this week. The poster presentations detailed:
Apr 02, 2018 04:01 pm ET
Aduro Biotech to Present at the H.C. Wainwright Annual Global Life Sciences Conference
BERKELEY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the H.C. Wainwright Annual Global Life Sciences Conference in...
Mar 14, 2018 04:31 pm ET
Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
Preclinical Data Showcases Immuno-Oncology Agents ADU-S100 STING Agonist, BION-1301 and ADU-1604 Antibodies 
Mar 14, 2018 04:01 pm ET
Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference
BERKELEY, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 28th Annual Oppenheimer Healthcare Conference in New York,...
Mar 07, 2018 04:01 pm ET
Aduro Biotech to Present at the 38th Annual Cowen Healthcare Conference
BERKELEY, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, will present at the 38th Annual Cowen Healthcare Conference in Boston, MA on Wednesday, March...
Mar 05, 2018 04:05 pm ET
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck (known as MSD outside the United States...
Mar 05, 2018 04:01 pm ET
Aduro Biotech Appoints Hans van Eenennaam Executive Vice President Antibody Research and Site Head, Aduro Biotech Europe
BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Hans van Eenennaam, Ph.D. has been promoted to executive vice president antibody research and site head of Aduro Biotech Europe. In his new...
Mar 01, 2018 04:01 pm ET
Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results
BERKELEY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the year ended December 31, 2017. Net loss for the fourth quarter and year ended December 31, 2017 was $26.1 million, or...
Mar 01, 2018 07:35 am ET
Analysis: Positioning to Benefit within Penumbra, Qualys, OraSure Technologies, Air Lease, Aduro Biotech, and Progenics Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Penumbra, Inc. (NYSE:PEN), Qualys, Inc. (NASDAQ:QLYS),...
Feb 08, 2018 04:31 pm ET
Aduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare Conference
BERKELEY, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Leerink Partners 7th Annual Global Healthcare Conference in...
Jan 05, 2018 08:00 am ET
Aduro Biotech Announces Management Changes
Jennifer Lew Appointed Chief Financial Officer
Jan 05, 2018 07:30 am ET
Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions — Future Expectations, Projections Moving into 2018
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals...
Jan 04, 2018 04:01 pm ET
Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 36th Annual J.P. Morgan Healthcare Conference in San...
Dec 20, 2017 08:00 am ET
Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent
BERKELEY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the United States Patent and Trademark Office has issued a new patent in Aduro’s portfolio...
Dec 18, 2017 08:00 am ET
Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma
-- Data Presented Recently at ASH Demonstrate BION-1301’s Blocking of TACI in Addition to BCMA Results in Inhibition of Regulatory T Cells --
Dec 12, 2017 08:00 am ET
Aduro Biotech Provides Update on CRS-207 Programs
--Conference Call to Review Program Updates Today at 8:30am ET--
Dec 11, 2017 04:01 pm ET
Aduro Biotech to Host a Program Update Call
BERKELEY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the company will host a conference call to provide an update on its programs tomorrow,...
Nov 21, 2017 01:00 am ET
Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration
BERKELEY, Calif. and OSS, Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that Wiebe Olijve, PhD, a member of its scientific advisory board and...
Nov 10, 2017 08:00 am ET
Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
Poster #335 to be Presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer
Nov 01, 2017 09:05 am ET
Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting
BERKELEY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced preclinical data presentations relating to BION-1301, the company’s anti-APRIL targeting B-select monoclonal antibody, to be given at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017. ...
Nov 01, 2017 09:05 am ET
Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting
BERKELEY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced preclinical data presentations relating to BION-1301, the company’s anti-APRIL targeting B-select monoclonal antibody, to be given...
Sep 26, 2017 08:01 am ET
Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas
BERKELEY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the first patient has been dosed in the Phase 1b dose escalation and dose expansion clinical trial (see www.clinicaltrials.gov, identifier NCT03172936) designed to evaluate the safety and efficacy of ADU-S100 (also known as MIW815), a novel STING pathway activator, in combination with PDR001, Novartis’ investigational PD-1 checkpoint inhibitor, for the treatment of advanced/metastatic solid tumors or lymphomas...
Sep 18, 2017 04:02 pm ET
Aduro Biotech to Present at Three Investor Conferences in the Second Half of September
BERKELEY, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at three investor conferences in New York, NY in the second half of September 2017....
Aug 31, 2017 04:05 pm ET
Aduro Biotech to Present at Three Investor Conferences in the First Half of September
BERKELEY, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at the following investor conferences in New York, NY the first half of September 2017:...
Aug 03, 2017 04:05 pm ET
Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference
BERKELEY, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at the 37th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 10, 2017, at 12:00 pm Eastern Time....
Aug 02, 2017 04:01 pm ET
Aduro Biotech Reports Second Quarter 2017 Financial Results
BERKELEY, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the second quarter of 2017. Net loss for the second quarter 2017 was $19.4 million, or $0.27 per share, and for the six months ended June 30, 2017 net loss was $41.2 million, or $0.59 per share, compared to net income of $2.3 million, or $0.04 per share, and net loss of $26.5 million, or $0.41 per share, respectively, for the same periods in 2016....
Jul 27, 2017 08:00 am ET
Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017
BERKELEY, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that Andrea van Elsas, Ph.D., chief scientific officer of the company’s subsidiary Aduro Biotech Europe, will be appointed chief scientific officer of Aduro Biotech effective September 1, 2017. Thomas Dubensky, Jr., Ph.D., has resigned from this post effective August 31, 2017 to pursue his interest in running his own discovery and research company. Dr. Dubensky will provide counsel to the company through a consultin...
Jun 29, 2017 04:05 pm ET
Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma
BERKELEY, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced  the initiation of the Phase 2 clinical study designed to evaluate the tolerability, safety and efficacy of CRS-207, Aduro’s lead listeria-based immunotherapy construct (LADD), in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada), for the treatment of patients with gastroesophageal adenocarcinoma who have failed two prior chemothera...
Jun 28, 2017 04:05 pm ET
Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural M
BERKELEY, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient has been dosed in the company’s Phase 2 clinical trial in malignant pleural mesothelioma (MPM). The trial, which will involve approximately 35 patients, will evaluate the tolerability, safety and efficacy of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the...
May 02, 2017 04:05 pm ET
Aduro Biotech Reports First Quarter 2017 Financial Results
BERKELEY, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter ended March 31, 2017. Net loss for the first quarter of 2017 was $21.8 million, or $0.32 per share, compared to a net loss of $28.8 million, or $0.45 per share for the same period in 2016. ...
Apr 20, 2017 04:05 pm ET
Aduro Biotech Announces Management Promotions
BERKELEY, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced the promotion of Michele DeVries to vice president, regulatory affairs and Celeste Ferber to vice president, associate general counsel....
Mar 02, 2017 04:05 pm ET
Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference
BERKELEY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced data presentations relating to its technology platforms to be given at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference: Taking a Place in Mainstream taking place in Whistler, B.C., Canada, March 19 through 23, 2017. ...
Feb 28, 2017 08:00 am ET
Aduro Biotech to Present at Two Investor Conferences in March
BERKELEY, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that it will present at two investor conferences in March 2017. On Monday, March 6, 2017 at 4:40 pm Eastern Time, Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 37th Cowen and Company Annual Healthcare Conference in Boston, MA.  On Monday, March 13, 2017 at 10:00 am Pacific Time, Gregory W. Schafer, chief operating officer of Aduro, will present at the 29th Annual ROTH Conference in Dana Point, CA....
Jan 19, 2017 08:00 am ET
Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology
BERKELEY, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced an exclusive license agreement with Stanford University for state-of-the-art neoantigen identification technology developed by Dr. Hanlee Ji, associate professor of medicine at Stanford.  Aduro will leverage its proprietary live, attenuated double-deleted Listeria (LADD) immunotherapy platform to engineer personalized LADD-based cancer therapies (pLADD) encoding multiple neoantigens identified through this technol...
Jan 09, 2017 08:00 am ET
Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer
BERKELEY, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today a clinical collaboration with Merck (known as MSD outside the United States and Canada). The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of gastric cancer....
Dec 27, 2016 04:00 pm ET
Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2017, at 10:00 am Pacific Time....
Dec 03, 2016 12:00 pm ET
Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma
BERKELEY, Calif. and OSS, The Netherlands, Dec. 03, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced the presentation of data from preclinical studies supporting the clinical development of the company’s proprietary monoclonal antibody (mAb) BION-1301, a humanized anti-APRIL (A PRoliferation-Inducing Ligand) antibody for the treatment of multiple myeloma.  Data from these in vivo and in vitro preclinical studies demonstrated that BION-1301 effectively neutralized APRIL, preventing its bin...
Nov 21, 2016 08:00 am ET
Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials
BERKELEY, Calif., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies....
Nov 12, 2016 08:00 am ET
Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial
Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Continues to Show Clinical Activity of CRS-207...
Nov 07, 2016 08:00 am ET
Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100
BERKELEY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted an oral presentation given by the company’s chief scientific officer, Thomas Dubensky Jr., Ph.D., at the 4th European Society of Medical Oncology (ESMO) Symposium on Immuno-Oncology held last week in Lausanne, Switzerland.  The data, generated from multiple preclinical models, demonstrated important changes in the tumor microenvironment and the activation of acute and systemic tumor-specific immune cell responses following intratumoral administration of ADU-S100 (also known as MIW815), a...
Oct 24, 2016 08:00 am ET
Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials
--Current Clinical Trial Patients Are Continuing to Receive LADD Treatment--  --Company to Host Conference Call Today at 6 a.m. PT/9 a.m. ET--...
Oct 23, 2016 04:00 pm ET
Aduro Biotech to Host Conference Call
BERKELEY, Calif., Oct. 23, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it will hold a conference call to provide a corporate update tomorrow, October 24, 2016, at 6:00 a.m. PT. To participate in the conference call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and refer to conference ID 4915023. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the general public at http://edge.media-server.com/m/p/rk79zbwm and under the Investors section of the co...
Sep 27, 2016 08:00 am ET
Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitors to Increase Antitumor Efficacy
BERKELEY, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted two posters presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-AACR) in New York. The preclinical data demonstrate positive changes in the tumor microenvironment and induction of a tumor-specific immune response by Aduro’s LADD (listeria-based immunotherapy construct) and STING (Stimulator of Interferon Genes) Pathway Activator immunotherapy platform technologies. Importantly, adding a PD-1 blockade to either immunotherapy regimen significantly...
Sep 26, 2016 08:00 am ET
Aduro Biotech’s Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce
150.jpgBERKELEY, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that Stephen T. Isaacs, the company’s chairman, president and CEO, will receive the Berkeley Chamber of Commerce Visionary Award. One of three recipients for 2016, Mr. Isaacs was recognized for his commitment to innovation and his visionary leadership within the city of Berkeley....
Sep 22, 2016 08:00 am ET
Aduro Biotech to Present at LEERINK Partners Roundtable Series
BERKELEY, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Thursday, September 29, 2016, at 8:00 am Eastern Time....
Sep 06, 2016 08:00 am ET
Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer
BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the appointment of Natalie R. Sacks, M.D., to the position of chief medical officer....
Sep 01, 2016 08:00 am ET
Aduro Biotech Announces New Corporate Offices and Laboratory Space
BERKELEY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the opening of a new corporate office and laboratory facility, which will serve as the company’s new global headquarters for its U.S. and European operations....
Aug 04, 2016 08:00 am ET
Aduro Biotech to Present at Canaccord Genuity Growth Conference
BERKELEY, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at the 36th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 11, 2016, at 2:00 pm Eastern Time....
Aug 03, 2016 04:01 pm ET
Aduro Biotech Reports Second Quarter 2016 Financial Results
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the second quarter 2016. Net income for the three months ended June 30, 2016 was $2.3 million, or $0.04 per share, and for the six months ended June 30, 2016 net loss was $26.5 million, or $0.41 per share, compared to a net loss of $26.3 million, or $0.50 per share, and $42.9 million, or $1.61 per share respectively, for the same periods in 2015. ...
Jun 09, 2016 08:00 am ET
Aduro Biotech to Present at NASDAQ Investor Conference
BERKELEY, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 34th NASDAQ Investor Conference on Thursday, June 16, 2016, at 10:15 am British Summer Time....
Jun 04, 2016 09:00 am ET
Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO
BERKELEY, Calif., June 04, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of updated data from an ongoing Phase 1b clinical trial of its immunotherapy product candidate CRS-207 in combination with pemetrexed and cisplatin (standard of care chemotherapy) as front-line treatment for patients with unresectable malignant pleural mesothelioma (MPM). The results from the first of two cohorts were presented today in a poster presentation at the 2016 American Society of Clinical Oncology Meeting (ASCO) held in Chicago. Of the 36 evaluable patients, diseas...
May 16, 2016 03:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aduro BioTech, Inc. - ADRO
NEW YORK, May 16, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aduro BioTech, Inc. ("Aduro" or the "Company") (NASDAQ: ADRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
May 16, 2016 03:04 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aduro BioTech, Inc. (ADRO)
NEW YORK, May 16, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Aduro BioTech, Inc. ("Aduro" or the "Company") (NASDAQ: ADRO).  Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at [email protected] or 212-697-6484. 
May 16, 2016 08:30 am ET
Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer
BERKELEY, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting. Median overall survival (MOS) in this third-line and greater setting was 3.8 months for patients treated with the immunotherapy regimen of CRS-207 and GVAX Pancreas, 5.4 months for patients treated with CRS-207 alone and 4.6 months for patients administered chemotherapy. There were n...
May 15, 2016 08:00 am ET
Aduro Biotech to Host Conference Call
BERKELEY, Calif., May 15, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that it will hold a conference call tomorrow, May 16, 2016, at 6:00 am Pacific Time. To participate in the conference call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and refer to conference ID 14354499. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the general public under the Investors section of the company’s website at www.aduro.com. ...
May 12, 2016 04:00 pm ET
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors
BERKELEY, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient has been dosed in a Phase 1 trial for ADU-S100 (also known as MIW815), a novel STING (Stimulator of Interferon Genes) pathway activator. Activation of the STING pathway in tumors has been shown to be a critical step to initiate an innate response that may lead to a systemic adaptive tumor-specific immune response. Novartis, Aduro’s collaborator for STING pathway activator compounds in the field of oncology, is conducting the study. The achievement of this milestone tr...
May 11, 2016 08:00 am ET
Aduro Biotech Announces Management Promotions
BERKELEY, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the promotion of Dirk Brockstedt, Ph.D., to executive vice president, research and development; Nancy Kaplan to vice president, human resources and facility operations; Anne Moon, Ph.D., to vice president, project management and team leader; and Justin Skoble, Ph.D., to vice president, technical operations....
May 02, 2016 04:00 pm ET
Aduro Biotech Announces First Quarter 2016 Financial Results
BERKELEY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter 2016.  For the three months ended March 31, 2016, net loss was $28.8 million, or $0.45 per share, compared to a net loss of $16.6 million, or $39.97 per share for the same period in 2015. ...
Apr 28, 2016 09:00 am ET
Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma
BERKELEY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the publication of a pivotal paper elucidating the roles of B cell maturation antigen (BCMA) and its ligand A PRoliferation-Inducing Ligand (APRIL) in multiple myeloma, highlighting the potential of its proprietary monoclonal antibody (mAb) BION-1301 targeting APRIL. The authors demonstrated through in vivo and in vitro preclinical studies that the APRIL/BCMA ligand/receptor pair drives multiple myeloma tumor growth and survival, and activates immunosuppressive mechanisms that allow the t...
Apr 27, 2016 08:00 am ET
Aduro Biotech to Present at Two Upcoming Investor Conferences
BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following upcoming investor conferences:...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.